Hormone replacement therapy in the peri-menopausal and postmenopausal period: More than half of the women were treated for more than one year;Hormoonsuppletietherapie in de peri- en postmenopauzale periode: Bij meer dan de helft van de vrouwen langer dan een jaar

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 38, 2003, Pages 1853-1855

  Tobi, H ^a   Van den Berg, P B ^a   Brouwers, J R B J ^a,b   De Jong van den Berg, L T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; ORAL CONTRACEPTION; POSTMENOPAUSE; PREVALENCE; TREATMENT OUTCOME;

AGE FACTORS; AGED; CONTRACEPTIVES, ORAL; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; NETHERLANDS; TIME FACTORS;

EID: 0141621824     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
3. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53.
4. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-4.
5. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Million Women Study Collaborators. Lancet 2003;362:419-27.
6. Berg P van den, Stuurman A, Jong-van den Berg LTW de. Het gebruik van hormoonsubstitutie bij vrouwen: informatie vooraf is essentieel. Pharm Weekbl 2000;135:388-93.
7. Lau HS, Boer A de, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50: 619-25.
8. Monster TBM, Janssen WMT, Jong PE de, Jong-van den Berg LTW de. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002;11:379-84.
9. Tobi H, Berg PB van den, Jong-van den Berg LTW de. The InterAction database: synergy of science and practice in pharmacy. Lect Notes Comput Sc 2000;1933:206-11.
10. G-standaard [maandelijkse uitgave]. Den Haag: Z-index; 1997-2002.
11. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
12. Hormonen slikken is gevaarlijk - maar hoe gevaarlijk. NRC Handelsblad 14 augustus 2003. p. 3.
13. Gebruik hormoonpil in Nederland onderschat. De Volkskrant 16 augustus 2003. p. 1.
14. Nelson HD. Assessing benefits and harms of hormone replacement therapy: clinical applications. JAMA 2002;288:882-4.